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ABSTRACT: Lycopene (LYC) has been correlated with the reduction of certain cancers and chronic diseases. However, the
existence and biofunctionality of degraded, oxidized, and biotransformed LYC products in vivo have not been revealed.
Therefore, this study aimed to screen and elucidate the potential bioactive lycopene-derived products in breast-cancer and non-
cancerous cells. LYC-oxidation or -cleavage products were generated using KMnO4. These oxidation products were separated as
fractions I−III by silica column chromatography using gradient solvent systems. Further, LC-MS/MS (ESI)+ was used to
elucidate their possible fragmentation patterns and structures. Fraction II showed higher cytotoxicity (IC50 value of
64.5 μM), cellular uptake, and apoptosis-inducing activity in MCF-7 cells. This fraction consists of major peak m/z 323,
identiﬁed as apo-8,6′-carotendial. The cytotoxicity-inducing activity may be due to partial ROS generation with mitochondrial
dysfunction. Further, the role of apo-8,6′-carotendial in the induction of apoptosis is demonstrated for the ﬁrst time. These
results illustrated that LYC-oxidation derivatives or metabolites are involved in growth inhibition of cancer cells. Exploration of
speciﬁc oxidized-carotenoid products will give further insight into the ﬁeld of nutritional biochemistry.
KEYWORDS: lycopene-oxidation products, breast cancer, apoptosis, reactive oxygen species, mitochondrial membrane potential
■ INTRODUCTION
Several epidemiological studies have shown a relationship
between lycopene (LYC) consumption and decreased risks of
cancer and other chronic diseases.1−4 Studies have suggested
that LYC decreases the risks for certain types of cancers,
including breast cancer.5,6 The eﬀects of LYC are attributed to
its antioxidant and cell-signaling properties.7 The unique chemi-
cal properties of LYC are very sensitive to oxidative modiﬁcation
and degradation.8 Stability studies have shown isomerization
and degradation of (all-E)-LYC when exposed to light, oxygen,
and high temperatures.9 In general, carotenoids are more
prone to various modiﬁcations such as hydrogenation, dehy-
drogenation, double-bond migration, chain shortening or exten-
sion, rearrangement, isomerization, oxidation, and combinations
of these processes, resulting in numerous products.10 Apart from
these, carotenoid-oxidation metabolites may also be formed as a
result of the presence of monooxygenase, cyclooxygenase, and
dioxygenase enzymes.11 Typically, the breakdown of lycopene
occurs through isomerization followed by oxidation to yield
epoxides, or it undergoes eccentric cleavage by carotene-9′,10′-
monooxygenase (CMO-II) to form apo-lycopenoids.12,13 The
conversion and biological functions of β-carotene metabolites
are well documented in humans;14 however, the bioactivities of
speciﬁc LYC-oxidation derivatives are poorly explained.
Carotenoid metabolites and oxidized-carotenoid products are
reported to be involved in the chemoprevention of cancer.15−17
Previously, lycopene-oxidation metabolites have been identiﬁed
in vitro and in vivo.18−24 Few notable studies support the con-
cept that the biological activities of lycopene may be mediated
by its oxidative-cleavage products.25−28 Even though studies
claim the possible role of carotenoid metabolites, the speciﬁc
functions of oxidative derivatives and metabolites or fractions
rich in them are not well explained, as compared with those of
the parent compound. Previously, we speculated that oxidized-
LYC mixtures might have possible cytotoxic eﬀects, resulting in
the inhibition of diﬀerent cancer cells.29 The enzymatic- and
oxidative-degradation products of LYC have ascertained health
beneﬁts; however, the fates of these derivatives and their anti-
cancer activities are still not well detailed. Furthermore, eluci-
dation of such potential components and oxidation products is
considered to be important in understanding their role against
chronic-disease progression. Hence, the present study was
aimed at isolating and identifying the major oxidative-cleavage
products of LYC and elucidating their anticancer properties.
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■ MATERIALS AND METHODS
Chemicals. (all-E)-Lycopene (>90%), potassium permanganate,
dichloro-dihydro-ﬂuorescein diacetate (DCHF-DA) dye, 4,6-diamidi-
no-2-phenylindole dilactate (DAPI), butylated hydroxytoluene
(BHT), 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolocarbo-
cyanine iodide (JC-1 dye), and tetrahydrofuran (stabilized with
BHT) were purchased from Sigma-Aldrich. HPLC-grade methanol,
acetonitrile, dichloromethane (DCM), isopropyl alcohol, and tetra-
hydrofuran (THF) and PVDF syringe ﬁlters (0.45 μm) were procured
from Merck. Minimum essential medium (MEM), fetal-bovine serum
(FBS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT), antibiotic−antimycotic solution, calcium magnesium free
phosphate-buﬀered saline (PBS), and cell-culture consumables were
purchased from Hi-Media Chemical Laboratories. The FITC−
annexin V apoptosis-detection kit was purchased from BD
Pharmingen (BD Bioscience). All other chemicals and solvents
were of analytical grade and were purchased from Sisco Research
Laboratories.
Isolation of LYC from Tomato. Ripened tomatoes were utilized
for LYC extraction (Indian hybrid) as per our earlier method.30 The
peak identities, absorption maxima (λmax), and characteristic UV−
visible spectrum of isolated LYC were conﬁrmed by LC-MS/MS
analysis using a reference standard.30 Extraction and preparation of
LYC from sample and standard were carried out under dim, yellow
light at 4 °C to prevent isomerization and degradation.
Oxidation of LYC. LYC isolated from tomato was subjected to
oxidation by using KMnO4 as per the procedure of Caris-Veyrat
et al.20 In brief, LYC (30 mg) and cetyltrimethylammonium bromide
(6 mg) was dissolved in 30 mL of DCM/toluene (1:1 ratio). The
oxidation of LYC was initiated by adding 1.5 mL of aqueous solution
of KMnO4 stock (135 mg in 9 mL of water) and stirring with a mag-
netic stirrer for 30 min at 26 ± 2 °C. The organic phase containing
LYC-oxidation products was separated by repeated washings with
double distilled water (10 mL), ﬁltration through a PVDF ﬁlter
(0.45 μm), and drying on sodium sulfate under a nitrogen environ-
ment. The residue of the LYC-oxidation mixture redissolved in
petroleum ether and was ﬁltered with a PVDF ﬁlter to remove the
remaining KMnO4. LC-MS/MS ESI
+ve mode was applied to analyze
crude LYC-oxidation products and diﬀerent fractions obtained by
gradient open-column chromatography. Aliquots of the oxidized
fractions were used for cell-culture treatments or sealed under a nitro-
gen environment and stored at −80 °C in amber vials.
Fractionation of LYC-Oxidation Products. Open-column
chromatography (OCC, 20 × 1.5 cm) on silica G (particle size
70−230 mesh) was employed to separate LYC-oxidation products
using speciﬁc gradient solvent systems. In brief, an aliquot of the LYC-
oxidation products was dried under a nitrogen environment and
redissolved in a known volume of hexane/acetone (50:50, v/v), and
applied to OCC. The oxidation products were eluted using hexane/
acetone in the ratios 90:10, 80:20, and 70:30 (v/v), and each fraction
was collected separately in amber vials and subjected to HPLC
analysis. LC-MS/MS analysis conﬁrmed the peak identities and the
respective spectra of each fraction. Further, the bioactive-rich fraction
was subjected to MS/MS analysis to understand its fragmentation
pattern.
HPLC Analysis of LYC-Oxidation Products. Chromatographic
separation of the LYC-oxidation products was standardized using an
AB SCIEX API 2000 system (Applied Biosystems) with a C30
column (5 μm, 250 × 4.6 mm; Princeton Chromatography Inc.). The
mobile phase, consisting of acetonitrile/methanol/isopropyl alcohol
(40:40:20, v/v/v) under isocratic conditions with a ﬂow rate of
0.8 mL/min, was monitored at 420 and 450 nm using a UV detector.
An aliquot (20 μL) of LYC and its oxidation products was injected on
the column, which was maintained at 40 °C. Data acquisition and
processing were carried out using Analyst version 1.5 software
(Applied Biosystems).
LC-MS/MS Conditions for Analysis of LYC-Oxidation
Products. Analysis of LYC-oxidation products was performed using
an AB SCIEX API 2000 mass spectrometer (Applied Biosystems) via
an ESI source operated in positive-ion mode. An aliquot (20 μL) of
LYC and its oxidation products (∼20 μg/mL) was injected onto the
column. The conditions used are the same as those mentioned for
HPLC analysis. The instrument conditions were the following: an ion-
source voltage of 3500 V, a declustering potential of 20 V, a focusing
potential of 400 V, an entrance potential of 10 V, a source tem-
perature of 420 °C, GS-I at 50 psi, GS-II at 60 psi, and a curtain gas of
nitrogen at 30 psi. Mass spectra of the LYC-oxidation products were
recorded with an m/z 50−1000 scan range at 450 nm. Data were
processed by using Analyst version 1.5 software (Applied Biosystems).
Further, the collision-induced-ion-dissociation spectra were recorded
and compared with those of the molecular ions of the LYC-oxidation
Table 1. Structures of Apo-lycopenals and Apo-carotendials Obtained from the Oxidation of LYC by Potassium Permanganate
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products. A collision-induced-dissociation energy of 6 V was used to
check the fragmentation pattern. Because of the constraint in the
sample size and the unavailability of standards for LYC-oxidation
products, the possible structures were elucidated using Chemsketch
8.0 software (ACD Laboratories).
Furthermore, the samples were subjected to a Bruker impact HD
(Q-TOF) high-resolution mass spectrometer to conﬁrm the LYC-
oxidation products with higher accuracy (Supplementary Figure 1).
Culture Conditions and Viability Assay. MCF-7 cells were
obtained from the National Centre for Cell Science in Pune, India,
Figure 1. LC-MS/MS analysis and elucidation of possible LYC-oxidation products (fraction III, compound A and B; fraction II, compounds C−F;
fraction I, compounds G−J). MS/MS scan 391 > 331, 463 > 377, 338 > 321, 429 > 359, 449 > 312, 323 > 251, 351 > 281, 349 > 331, 417 > 347,
377 > 307.
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and cultured in standardized conditions.29 Cells were grown in MEM
medium supplemented with 10% heat-inactivated fetal-bovine serum,
4 mM glutamine, 40 g/mL penicillin, and 400 U/mL streptomycin.
Similarly, normal breast epithelial cells (MCF-10A, ATCC) were
cultured and maintained as per the previous report.31 Preliminarily,
we screened diﬀerent concentrations of lycopene (1−200 μM) and its
oxidation products (fractions I to III) for the cytotoxic assay. This
study demonstrated that rich fractions of LYC-oxidation products
showed cytotoxicity at higher concentrations (50, 100, and 200 μM
equivalent LYC concentrations). Hence, in the current study, we used
above optimal level (100 μM) of LYC concentration to compare its
activity with diﬀerent fractions of LYC-oxidation products for cell-
based assays. LYC and the diﬀerent fractions of LYC-oxidation
products obtained by OCC were dissolved in cell-culture-grade THF
and added to the cells in the medium at diﬀerent doses (quantiﬁed on
the basis of the equivalent concentrations of standard LYC, as per the
Zhang et al.21 method). The ﬁnal concentration of THF in the culture
medium was 0.5% (v/v). THF at this concentration did not induce
cytotoxicity. The cells were seeded into 96-well microtiter plates
(5000 cells/well). After 24 h of cultivation, cell viability was measured
using the MTT method as described previously.16
Apoptosis Detection. Apoptosis detection was performed with
an FITC−annexin V apoptosis-detection kit according to the manu-
facturer’s instructions. Brieﬂy, control and treated cells (1 × 105 cells/
well in 12-well plates) incubated for 24 h were collected, then washed
with ice-cold PBS, and centrifuged at 2500 rpm for 5 min. The cell
pellet was resuspended in the ice-cold 1× binding buﬀer, incubated
with FITC-conjugated annexin V and propidium iodide (PI) for 15 min
at room temperature in the dark. Before the analysis, the instrument
was calibrated with internal controls, such as unstained cells (negative
control) and stained cells (annexin V-FITC, PI, and annexin V-FITC
with PI control cells). The samples were immediately analyzed on a
FACS Verse ﬂow cytometer using the Diva analysis software.
Confocal Microscopy. LYC-oxidation-products (50 and100 μM)
untreated and treated cells were harvested after 24 h of incubation
and used for annexin V−FITC−PI and DAPI staining. Then, the cells
were observed under an inverted confocal laser-scanning microscope
(Ziess LSM 510 MK4), and the images were captured.
ROS Detection by Flow Cytometry. Control and treated cells
(2 × 105) were harvested after 24 h of incubation, washed with PBS,
and suspended in 1 mL of PBS. Afterward, DCFH-DA (10 μM) was
added, and the solution was incubated for 15 min in 5% CO2 at
37 °C. After incubation, the cells were washed and resuspended in
PBS and analyzed within 1 h on a FACS Verse ﬂow cytometer after
calibration with negative-control (unstained) and positive-control
(H2O2 treated) cells. The results were expressed as the ﬂuorescence
intensities of dichloroﬂuorescein, and the negative-control, treatment,
and H2O2-treated (positive control) cells were compared.
Detection of Loss of Mitochondrial Transmembrane
Potential (Dym). Modiﬁcations of the mitochondrial membrane
potential were analyzed by ﬂow cytometry using JC-1 dye, as
described earlier.32 Brieﬂy, MCF-7 cells were treated with either LYC
or its oxidation products (50−200 μM concentration) for 24 h. Then,
cells were incubated with JC-1 (0.5 mM) for 15 min at 37 °C and
subjected to ﬂow-cytometric analysis. The ratio of red to green ﬂuo-
rescence was measured for each treatment and plotted. Cells treated
with 2,4-dinitrophenol (2,4-DNP) were considered the positive control.
Cellular Uptake of LYC versus Cellular Uptake of Its
Oxidized Products. MCF-7 cells (106) in 75 cm2 ﬂasks (n = 3)
were treated with 100 μM puriﬁed LYC or its bioactive oxidation
products (fraction II). After incubation for 24 h, cells were harvested,
washed using MEM, and extracted with suitable solvent systems. The
LYC and oxidized-LYC contents of all the treated cells were quan-
tiﬁed by HPLC and expressed after subtracting the contents of
carotenoids adherent to the cell surfaces as determined at 4 °C.33
Statistical Analysis. The data were tested for homogeneity of
variances by the Bartlett test. When homogeneous variances were
conﬁrmed, the data were further analyzed using ANOVA (GraphPad
Prism 5.1. software). Tukey’s test evaluated the diﬀerences between
the treatment and control groups. Signiﬁcant diﬀerences between the
experimental samples were considered at P < 0.05.
■ RESULTS
Lycopenals Formed with Potassium Permanganate.
LC-MS/MS analysis of KMnO4 induced LYC-oxidation prod-
ucts showing the presence of single-oxidative-cleavage and
Figure 2. LC-MS/MS analysis of LYC-oxidation products (fraction II major peak, m/z 323).
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double-oxidative-cleavage products of LYC. The single-oxidative-
cleavage compounds contained an aldehyde or a ketone group at
one end and were identiﬁed as apo-lycopenal and apo-lycopenone,
respectively. The second category of oxidation products contained
two aldehyde end groups and was identiﬁed as apo-carotendials.
The chemical structures of the apo-lycopenals, apo-lycopenones,
and apo-carotendials are shown in Table 1. Treatment with
KMnO4 resulted in cleavage of the carbon−carbon double
bonds of LYC, yielding a series of apo-lycopenals and apo-
carotendials. The separation of these cleaved-LYC products
was achieved using a C30 column (Figure 1). The lycopenals
and apo-carotendials were eluted on a C30 column in the
following order: (2E,4E,6E,8E,10E,12E,14E,16E,18E)-
2,6,11,15,19-pentamethyldocosa-2,4,6,8,10,12,14,16,18-nonae-
nedial (A, 19.73%), (4E,6E,8E,10E,12E,14E,16E,18E,20E,22E)-
2,6,10,15,19,23,27-heptamethyloctacosa-2,4,6,8,10,12,14,16,18,-
20,22,26-dodecaene (B, 7.5%), (4E,6E,8E,10E,12E,14E,16E)-
4,8,12,17-tetramethyl-18-oxononadeca-4,6,8,10,12,14,16-heptae-
nal (C, 13.5%), (2E,4E,6E,8E,10E,12E,14E,16E)-4,9,13,17,21-
pentamethyldocosa-2,4,6,8,10,12,14,16,20-nonaenal (D, 3.9%),
(2E,4E,6E,8E,10E,12E,14E,16E,18E,20E)-4,8,13,17,21-pen-
tamethyltetracosa-2,4,6,8,10,12,14,16,18,20-decaenedioic acid
(E, 4.2%), (2E,4E,6E,8E,10E,12E,14E,16E)-2,6,11,15-tetrame-
thyloctadeca-2,4,6,8,10,12,14,16-octaenedial (F, 23.2%),
(2E,4E,6E,8E,10E,12E,14E)-2,7,11,15,19-pentamethylicosa-
2,4,6,8,10,12,14,18-octaenal (apo-12′-lycopenal, G, 10.8%),
apo-5,6′-carotendial (H, 4.9%), (2E,4E 6E,8E,10E,12E,14E,-
16E,18E)-2,6,11,15,19,23-hexamethyl tetracosa-2,4,6,8,10,12,-
14,16,18,22-decaenal (apo-8′-lycopenal, I , 0.29%),
(2E,4E,6E,8E,10E,12E,14E,16E)-4,9,13,17,21-pentamethyldo-
cosa-2,4,6,8,10,12,14,16,20-nonaenal (apo-10′-lycopenal, J,
0.15%; Figure 1). The elution of the rich fraction of LYC-
oxidation products was obtained by OCC using a hexane/
acetone gradient solvent system with the following ratios: 90:10,
80:20, and 70:30 (v/v). A major peak in fraction 1 was identiﬁed
and designated as apo-12′-lycopenal (G). Fraction 2 consisted of
apo-8,6′-carotendial (F, (2E,4E,6E,8E,10E,12E,14E,16E)-
2,6,11,15-tetramethyloctadeca-2,4,6,8,10,12,14,16-octaenedial),
and fraction 3 consisted of (2E,4E,6E,8E,10E,12E,14E,16E,18E)-
2,6,11,15,19-pentamethyldocosa-2,4,6,8,10,12,14,16,18-nonaene-
dial (A), as a major peak. Fractions of LYC-cleavage products
(fractions I−III) were further evaluated in terms of their bioac-
tive roles in cancer and normal cell lines. Further, MS/MS
analysis of the bioactive LYC-cleavage products was done to
understand their fragmentation patterns (Figure 2).
Eﬀect of LYC-Oxidation Products on Cell Viability.
The cytotoxicity of fractions I to III of LYC-oxidation products
on MCF-7 cells is shown in Figure 3. Among the fractions
evaluated, fraction II, rich in apo-8,6′-carotendial, strongly
inhibited cell viability. The percent cell viability of MCF-7 cells
was decreased by 57.6 (fraction 1), 77.5 (fraction II), and
54.5% (fraction III) as compared with the control. The IC50
concentration of fraction II was found to be 64.5 μM equiv-
alent LYC concentration in MCF-7 cells.
Apoptosis Induction of LYC-Oxidation Products. An
increase in apoptosis was observed in MCF-7 cells treated with
fraction II (Figure 4). The inﬂuence of fraction II on apoptosis
was further conﬁrmed by annexin V-FITC−PI staining as
shown in Figure 4. Results of confocal-microscopic observation
showed more early and late apoptosis and nuclear con-
densations in the treated cells than in the control (Figure 5).
Intracellular ROS Generation. ROS generation is con-
sidered one of the intermediate steps during activation of
apoptosis. The levels of ROS were examined on the basis of
the ﬂuorescence of DCFDA. The inﬂuence of LYC and its
oxidized fraction II on intracellular ROS levels in MCF-7 cells
are shown in Figure 6. Fraction II increased ROS levels at the
lower concentration (50 μM) and decreased them at a higher
concentration (100 μM). Flow-cytometric evaluation showed
no detectable levels of ROS production upon treatment with
fraction II. The levels of ROS in the control cells and LYC-
treated cells were lower by 13.1 and 10.1% than those in the
fraction II treated cells at the lower concentration, and diﬀer-
ences not detected at the higher concentration. The percentage
of ROS in the positive control was found to be 81.3%.
Induction of the Loss of Mitochondrial Transmem-
brane Potential (Dym) by LYC-Oxidation Fraction II.
Loss of mitochondrial transmembrane potential (Dym) is well-
known to be an early event during apoptosis. We measured the
loss of mitochondrial membrane potential of LYC-treated and
fraction II treated MCF-7 cells (24 h) by ﬂow cytometry using
JC-1 dye. Dym was measured from the shift in the ratio of red- to
green-ﬂuorescence-emitting cells after treatment. Results showed
an increase in green ﬂuorescence in the fraction II treated cells in
a concentration-dependent manner, indicating a loss of mitochon-
drial transmembrane potential in treated cells (Figure 7). Thus,
the data suggest that the oxidation products (fraction II) induce
depolarization and mitochondrial-transmembrane-potential col-
lapse in the cells, leading to activation of apoptosis.
Figure 3. (a) Eﬀects of LYC and oxidized fractions I−III (1−200 μM)
on viability of MCF-7 cancer cell lines. (b) Eﬀects of LYC and
oxidized fractions I−III (1−200 μM) on viability of MCF-10A cell
lines. The asterisks indicate values that are signiﬁcantly diﬀerent from
the control (*P < 0.05, **P < 0.001, ***P < 0.0001). Statistical com-
parisons were made by one-way ANOVA followed by Tukey’s test.
Values are means ± SD (n = 3).
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Cellular Uptake of LYC versus Cellular Uptake of Its
Oxidized Products. The cellular uptake of LYC and its oxi-
dation products (fractions I−III) was in the order of fraction
II > fraction I > fraction III > LYC (Figure 8). The oxidation
products showed higher cellular uptake compared with intact
LYC.
■ DISCUSSION
Studies have reported that carotenoid-rich diets are associated
with reduced risks of certain cancers. Among carotenoids, LYC
has gained special attention because of the worldwide con-
sumption of tomato and its products. Further, higher levels of
LYC in plasma and tissues are positively correlated with the
reduction of chronic diseases, including cancer.34,35 In this
regard, many studies have attempted to elucidate the possible
roles of carotenoids, mainly β-carotene, LYC, and lutein, on
the modulation of cancer progression. In contrast, few reports
have shown insigniﬁcant eﬀects of carotenoids on cancers both
in vitro and in vivo.36−39 Subsequently, studies were under-
taken on β-carotene and LYC metabolites to test the hypoth-
esis that the metabolites render higher antiproliferative eﬀects
on cancer cells than parent molecules. However, there is no
detailed study, even after two decades of research, on the
bioactivities of carotenoid metabolites or oxidation products
because of the unavailability of standards, low concentrations
and stabilities, and challenging issues in isolation and charac-
terization from biological samples. In the present study, we
demonstrated LYC-oxidation products, puriﬁed by column
chromatography using suitable solvent ratios and optimized
conditions, and the anticancer properties of fraction II, which
Figure 4. Detection of apoptosis induced by LYC (100 μM) and oxidized LYC (fraction II, 50−200 μM) in the MCF-7 cell line. Values are
means ± SD (n = 3). Ctrl, control; EA, early apoptosis; LA, late apoptosis.
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Figure 5. Apoptotic MCF-7 cells stained with annexin V−FITC−PI and examined under a microscope (100×) after treatment with fraction II (50
and 100 μM). DAPI was used as nuclear marker.
Figure 6. Eﬀects of LYC (100 μM) and oxidized LYC (fraction II, 50−200 μM) on the production of reactive oxygen species in the MCF-7 cell
line. The asterisks indicate values that are signiﬁcantly diﬀerent from the control (*P < 0.05, ***P < 0.0001). Statistical comparisons were made by
one-way ANOVA followed by Tukey’s test. Values are means ± SD (n = 3).
Journal of Agricultural and Food Chemistry Article
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is rich in apo-8,6′-carotendial. The apoptotic properties of
fraction II indicate an opportunity for its potential application.
We also attempted for the ﬁrst time to compare the anticancer
eﬀects of LYC with those of its oxidized fraction II. Several
reports have proposed possible cleavage patterns of LYC to
obtain its metabolites in vitro and in vivo.17,18,20,40
Studies have suggested that lycopene decreases the risk of
breast cancer.6,41−43 Further, Sharoni et al.27 suggested that
some of the cellular eﬀects of carotenoids are mediated through
their derivatives, formed either by chemical oxidation or by
enzymatic cleavage inside the cells. Also, Ford et al.44 dem-
onstrated that LYC and its metabolite apo-12′-lycopenal signiﬁ-
cantly suppressed the proliferation of cells through alteration of
cell-cycle regulation. However, our results are contradictory,
showing a non-signiﬁcant diﬀerence between intact LYC
treatment and control cells on apoptosis induction in MCF-7
cells. The apoptosis-inducing activity of LYC-oxidation pro-
ducts (fraction II with major peak apo-8,6′-carotendial) was
conﬁrmed by annexin V-FITC-PI and JC-1 staining (Figures 4−7)
and may be due to changes in polarity and cellular uptake
(Figure 8) when compared with LYC and other fractions. It is
evident from Figure 8 that fraction II cellular uptake is
comparatively higher than that of LYC. Studies demonstrated
that uptake rates and intracellular concentrations in a diﬀerent
stages of cells might play important roles in the chemo-
preventive eﬀects of lycopene.45 Cellular uptake of fraction II is
higher than that of other fractions and LYC, which may be due
to diﬀerences in their structures, polarities, and solubilities.46
Further, in the present study, a strong relationship among
fraction II accumulation, cytotoxicity, and cell antiproliferation
is evident. It is possible that cell growth modality, metabolic
status, and membrane composition may inﬂuence carotenoid
accumulation depending on cell type.47 Further, ROS gen-
eration is considered one of the intermediate steps during the
activation of apoptosis. In our study, we observed slightly
higher ROS levels at 50 μM concentrations and minimal levels
of ROS production upon fraction II treatment at higher
concentrations (Figure 7). We determined that ROS was
generated with fraction II at 50 μM, as ROS levels were
suppressed when treated in combination with N-acetylcysteine
(NAC), an ROS scavenger (Supplementary Figure 2). The
higher oxidative stress by fraction II with the 50 μM treatment
may be due to an imbalance in oxidants and antioxidants in the
cells. In case of the 100 and 200 μM concentration, decreased
ROS levels were evident as compared with in the 50 μM
fraction II treated cells (Figure 7). These contrasting results
were clariﬁed with repeated experiments. The higher ROS
Figure 7. Eﬀects of LYC (100 μM) and oxidized LYC (fraction II, 50−200 μM) on mitochondrial integrity in the MCF-7 cell line. The asterisks
indicate values that are signiﬁcantly diﬀerent from the control (**P < 0.001, ***P < 0.0001). Statistical comparisons were made by one-way
ANOVA followed by Tukey’s test. Values are means ± SD (n = 3).
Figure 8. Cellular uptake of LYC and its oxidation products at a 100 μM
equivalent LYC concentration. The asterisks indicate values that are
signiﬁcantly diﬀerent from those of LYC (**P < 0.001, ***P < 0.0001).
Statistical comparisons were made by one-way ANOVA followed by
Tukey’s test. Values are means ± SD (n = 3).
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levels at 50 μM may trigger apoptosis either through the
extrinsic or intrinsic pathway within a short period of exposure.
This could be the reason for minimal levels of ROS at 100 and
200 μM fraction II (similar to in the control), showing an
ROS-independent pathway. Interestingly, the percent apopto-
sis ratio and loss of mitochondrial potential increase signiﬁ-
cantly in a dose-dependent manner. The cell-death-induction
mechanism in the fraction II treated cells may be through
either an ROS-dependent or -independent pathway and still
needs to be detailed. The cell-viability results conﬁrmed that
LYC and its oxidized fractions did not aﬀect the normal cells
(MCF-10A) under the experimental conditions, suggesting
that LYC-oxidation products or metabolites have an important
function against cancer-cell proliferation. On the basis of the
current study, we propose that LYC-derived products,
especially apo-8,6′-carotendial, may have biological functions.
The overall results indicated the potentiality of LYC-derived
products as chemopreventive molecules. This observation gives
a platform to address the active roles of carotenoid-derived
products. Although the roles of speciﬁc carotenoid metabolites
need to be explored, this is challenging because of the fol-
lowing limitations: the unavailability of standards, coelution,
lower concentrations, and circulation in a biological system.
Furthermore, studies related to the anticancer properties and
molecular mechanisms of speciﬁc oxidation products, such as
cyclins, inhibitors of apoptosis proteins and caspase activities,
need to be addressed (under progress). The in vivo studies
related to the roles of these speciﬁc metabolites also necessitate
addressing. Apart from these, the lifespans (half-lives) of these
oxidation products and metabolites need to be compared in
isotopic-labeling studies to show further potentiality.
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Jimeńez-Farfań, D.; Cruz Salgado, A.; Serrano-García, N.; Osorio-
Rico, L.; Sotelo, J. Multiple molecular and cellular mechanisms of
action of lycopene in cancer inhibition. J. Evid. Based Complementary
Altern. Med. 2013, 2013, No. 705121.
(8) Britton, G. Structure and properties of carotenoids in relation to
function. FASEB J. 1995, 9, 1551−1558.
(9) Anguelova, T.; Warthesen, J. Lycopene stability in tomato
powders. J. Food Sci. 2000, 65, 67−70.
(10) Rodriguez-Amaya, D. B.; Kimura, M. HarvestPlus Handbook of
Carotenoid Analysis; HarvestPlus, 2004.
(11) Yeum, K. J.; Leekim, Y. C.; Yoon, S.; Lee, K. Y.; Park, I. S.; Lee,
K. S.; Kim, B. S.; Tang, G. W.; Russell, R. M.; Krinsky, N. I. Similar
metabolites formed from β-carotene by human gastricmucosal
homogenates, lipoxygenase, or linoleic-acid hydroperoxide. Arch.
Biochem. Biophys. 1995, 321, 167−174.
(12) Hu, K. Q.; Liu, C.; Ernst, H.; Krinsky, N. I.; Russell, R. M.;
Wang, X.-D. The biochemical characterization of ferret carotene-9′,
10′-monooxygenase catalyzing cleavage of carotenoids in vitro and in
vivo. J. Biol. Chem. 2006, 281, 19327−19338.
(13) Wang, X. D. Lycopene metabolism and its biological
significance. Am. J. Clin. Nutr. 2012, 96, 1214−1222.
(14) Nagao, A. Oxidative conversion of carotenoids to retinoids and
other products. J. Nutr. 2004, 134, 237−240.
(15) King, T. J.; Khachik, F.; Bortkiewicz, H.; Fukushima, L. H.;
Morioka, S.; Bertram, J. S. Metabolites of dietary carotenoids as
potential cancer preventive agents. Pure Appl. Chem. 1997, 69, 2135−
2140.
(16) Lakshminarayana, R.; Aruna, G.; Sathisha, U. V.; Dharmesh, S.
M.; Baskaran, V. Structural elucidation of possible lutein oxidation
products mediated through peroxyl radical inducer 2, 2′-Azobis (2-
Journal of Agricultural and Food Chemistry Article
DOI: 10.1021/acs.jafc.8b04850
J. Agric. Food Chem. 2018, 66, 11362−11371
11370
methylpropionamidine) dihydrochloride: Antioxidant and cytotoxic
influence of oxidized lutein in HeLa cells. Chem.-Biol. Interact. 2013,
203, 448−455.
(17) Arathi, B. P.; Sowmya, P. R.; Vijay, K.; Baskaran, V.;
Lakshminarayana, R. Metabolomics of carotenoids: The challenges
and prospects - A review. Trends Food Sci. Technol. 2015, 45, 105−
117.
(18) Khachik, F.; Spangler, C. J.; Smith, J. C.; Canfield, L. M.; Steck,
A.; Pfander, H. Identification, quantification, and relative concen-
trations of carotenoids and their metabolites in human milk and
serum. Anal. Chem. 1997, 69, 1873−1881.
(19) Kim, S. J.; Nara, E.; Kobayashi, H.; Terao, J.; Nagao, A.
Formation of cleavage products by autoxidation of lycopene. Lipids
2001, 36, 191−199.
(20) Caris-Veyrat, C.; Schmid, A.; Carail, M.; Böhm, V. Cleavage
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